STRATIS注册研究:大脑中动脉M2段取栓与M1段比较
STRATIS为前瞻性多中心非随机观察性注册研究,纳入984例急性缺血性卒中大血管闭塞患者,比较M2与M1闭塞经Solitaire支架取栓的结局。M2与M1成功再灌注率、良好功能结局及死亡率相似,但M2组症状性颅内出血率显著增高。
要点
- M2闭塞取栓成功再灌注率与M1相似,良好功能结局和死亡率无差异。
- M2闭塞取栓后24小时症状性颅内出血率显著高于M1闭塞。
- M1与M2闭塞的获益时间依赖性相似,M2取栓获益仍需进一步研究。
核心结论
- M2闭塞取栓可获得与M1相似的成功再灌注、良好功能结局和死亡率,但症状性颅内出血率增高。
- M1与M2闭塞的获益时间依赖性相似。
研究设计与样本
- STRATIS为前瞻性、多中心、非随机、观察性注册研究。
- 共纳入984例急性缺血性卒中大血管闭塞患者,其中M1闭塞538例(54.7%),M2闭塞170例(17.3%)。
- 患者以Solitaire支架取栓作为首选治疗,症状出现8小时内。
主要发现
- M1组平均基线NIHSS评分显著高于M2组(17.3±5.5 vs 15.7±5.0,P≤0.001)。
- 两组平均穿刺至血管再通时间无差异(46.0±27.8 vs 45.1±29.5分钟,P=0.75)。
- 成功再灌注(mTICI≥2b)率两组相似(91% vs 95%,P=0.09)。
- M2组24小时症状性颅内出血率显著高于M1组(4% vs 1%,P=0.01)。
- 良好功能结局(mRS 0–2)率(58% vs 59%,P=0.83)和死亡率(15% vs 14%,P=0.75)两组相似。
临床怎么用
- M2闭塞取栓可考虑用于经过选择的急性缺血性卒中患者,但需警惕症状性颅内出血风险。
- M2与M1闭塞的获益时间依赖性相似,取栓决策时间窗原则可参照大血管闭塞。
局限性
- 本研究为非随机观察性注册研究,M2与M1组间比较可能存在混杂。
- M2闭塞取栓的获益仍需进一步研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The safety and benefit of mechanical thrombectomy in the treatment of acute ischemic stroke patients with M2 segment middle cerebral artery occlusions remain uncertain. Here, we compare clinical and angiographic outcomes in M2 versus M1 occlusions in the STRATIS (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke) Registry. METHODS: The STRATIS Registry was a prospective, multicenter, nonrandomized, observational study of acute ischemic stroke large vessel occlusion patients treated with the Solitaire stent-retriever as the first-choice therapy within 8 hours from symptoms onset. Primary outcome was defined as functional disability at 3 months measured by dichotomized modified Rankin Scale. Secondary outcomes included reperfusion rates and rates of symptomatic intracranial hemorrhage. RESULTS: A total of 984 patients were included, of which 538 (54.7%) had M1 and 170 (17.3%) had M2 occlusions. Baseline demographics were well balanced within the groups, with the exception of mean baseline National Institutes of Health Stroke Scale score which was significantly higher in the M1 population (17.3±5.5 versus 15.7±5.0, P≤0.001). No difference was seen in mean puncture to revascularization times between the cohorts (46.0±27.8 versus 45.1±29.5 minutes, P=0.75). Rates of successful reperfusion (modified Thrombolysis in Cerebral Infarction≥2b) were similar between the groups (91% versus 95%, P=0.09). M2 patients had significantly increased rates of symptomatic ICH at 24 hours (4% versus 1%, P=0.01). Rates of good functional outcome (modified Rankin Scale score of 0–2; 58% versus 59%, P=0.83) and mortality (15% versus 14%, P=0.75) were similar between the 2 groups. There was no difference in the association of outcome and onset to groin puncture or onset to successful reperfusion in M1 and M2 occlusions. CONCLUSIONS: In the STRATIS Registry, M2 occlusions achieved similar rates of successful reperfusion, good functional outcome, and mortality, although increased rates of symptomatic ICH were demonstrated when compared with M1 occlusions. The time dependence of benefit was also similar between the 2 groups. Further studies are needed to understand the benefit of mechanical thrombectomy for M2 occlusions. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02239640.
引用
- Jumaa MA, Castonguay AC, Salahuddin H, et al. Middle Cerebral Artery M2 Thrombectomy in the STRATIS Registry. Stroke. 2021. PMID: 34311566. doi:10.1161/STROKEAHA.120.033951
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。